Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07624617 · ClinicalTrials.gov registry record · NA
Fast-Her: Fasting Effects on Breast Cancer Treatment
A NA study, sponsored by University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT07624617 is a NA study that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 15 participants.
The verdict
NCT07624617, a NA study, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
Interventions
- BEHAVIORAL Prolonged Fasting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2027-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07624617
The ClinicalTrials.gov registry entry for NCT07624617 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prolonged Fasting is the first listed.
NCT07624617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07624617 about?
NCT07624617 is a clinical study titled "Fast-Her: Fasting Effects on Breast Cancer Treatment". We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
What is the current status of trial NCT07624617?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-05-18. Estimated completion is 2027-07-01.
What interventions are being tested in trial NCT07624617?
The interventions under investigation include: Prolonged Fasting (BEHAVIORAL).
Who is sponsoring clinical trial NCT07624617?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.